As Gottlieb Resigns, Agency Left To Implement Myriad New Initiatives

FDA Commissioner Scott Gottlieb’s unexpected resignation leaves myriad agency policy and regulatory plans, many of which Gottlieb identified as key priorities, hanging in the balance. After his departure, which is slated for next month, FDA will be left to implement a number of major initiatives without his leadership. Among them are plans already in motion to: ramp up enforcement of e-cigarettes and potentially ban characterizing flavors in tobacco products; change and expand dietary supplement oversight; expand the nonprescription drug space;...